NotableResults first posted: Jul 30, 2026v19Show 4 more changesShow less
Primary endpoint revised
Trial status: Active, Not Recruiting to Completed
Study completion date changed from estimate of Dec 28, 2019 to Jun 19, 2020
Secondary endpoints: 2 to 5
MinorPrimary completion date changed from estimate of Dec 28, 2018 to Feb 4, 2013
Study completion date: Jun 28, 2019 to Dec 28, 2019
v18
NotablePrimary completion date: Dec 28, 2017 to Dec 28, 2018
Study completion date: Jun 28, 2018 to Jun 28, 2019
v17
NotablePrimary completion date: Jun 2016 to Dec 28, 2017
Study completion date: Jun 2017 to Jun 28, 2018
Start date: Dec 2004 to Dec 28, 2004
v16
NotablePrimary completion date: Jan 2015 to Jun 2016
Study completion date: Dec 2015 to Jun 2017
v15
Show 13 earlier versionsHide 13 earlier versions
NotablePrimary completion date: Jan 2014 to Jan 2015
Study completion date: Jan 2016 to Dec 2015
v14
NotablePrimary completion date: Jan 2013 to Jan 2014
Study completion date: Jan 2015 to Jan 2016
Study arms: 0 to 1
v13
MinorTrial status: Recruiting to Active, Not Recruitingv12Show 4 more changesShow less
Enrollment target: estimated 53 to confirmed 75
Primary completion date: Dec 2012 to Jan 2013
Study completion date: Dec 2014 to Jan 2015
Site details revised
NotablePrimary completion date: Jan 2012 to Dec 2012
Study completion date: Jan 2014 to Dec 2014
v11
NotablePrimary completion date: Jan 2010 to Jan 2012
Study completion date: Jan 2014
v10
2 versionsRe-verified since Jul 24, 2009, no change to tracked fieldsv8-v9
NotablePrimary completion date: Jun 2009 to Jan 2010v7
MinorPrimary completion date: Jun 2009
Secondary endpoints: 3 to 2
v6
MinorCollaborators: 2 to 3
Eligibility criteria shortened, about 3 words
Study title expanded, about 2 words
v5
MinorEligibility criteria expanded, about 19 words
Secondary endpoints revised (3)
Primary endpoint revised
v4
Re-verified, no change to tracked fieldsv3
MinorEligibility criteria revisedv2
Study First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is for people with advanced gastric or gastroesophageal cancer. This study is being done to find out how long it takes tumors to grow after patients take the drugs capecitabine, oxaliplatin and cetuximab. Capecitabine (also called Xeloda) is a drug that has been approved by the Food and Drug Administration (FDA). Capecitabine has been approved for treatment of cancer of the colon and rectum. Oxaliplatin is another drug approved by the FDA. Oxaliplatin is also approved for treatment of cancer of the colon and rectum. Cetuximab is also a drug approved by the FDA for the treatment of cancer of the colon and rectum, as well as cancer of the head and neck. Capecitabine, oxaliplatin and cetuximab are not approved for gastric or gastroesophageal cancer. They are considered experimental drugs for this study. The purpose of this study is to see how long it takes patients' tumors to progress when they are taking oxaliplatin and capecitabine. Another purpose is to see how many tumors respond to this drug combination. The investigators also want to see how long people live when taking these drugs. The side effects of this drug combination will also be evaluated. This study will also measure the levels of certain genes (the cell's blueprint) in tumors. These genes affect how peoples' bodies react to the cancer drugs. Genes will also be measured in the blood. The investigators want to see how these genes can predict response to these study drugs.